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Abstract
Background: Foot pain is common in rheumatoid arthritis and appears to persist despite modern day medical
management. Several clinical practice guidelines currently recommend the use of foot orthoses for the treatment of
foot pain in people with rheumatoid arthritis. However, an evidence gap currently exists concerning the comparative
clinical- and cost-effectiveness of prefabricated and customised foot orthoses in people with early rheumatoid arthritis.
Early intervention with orthotics may offer the best opportunity for positive therapeutic outcomes. The primary aim of
this study is to evaluate the comparative clinical- and cost-effectiveness of prefabricated versus customised orthoses for
reducing foot pain over 12 months.
Methods/design: This is a multi-centre two-arm parallel randomised controlled trial comparing prefabricated versus
customised orthoses in participants with early rheumatoid arthritis (< 2 years disease duration). A total of 160
(a minimum of 80 randomised to each arm) eligible participants will be recruited from United Kingdom National Health
Service Rheumatology Outpatient Clinics. The primary outcome will be foot pain measured via the Foot Function Index
pain subscale at 12 months. Secondary outcomes will include foot related impairments and disability via the Foot Impact
Scale for rheumatoid arthritis, global functional status via the Stanford Health Assessment Questionnaire, foot disease
activity via the Rheumatoid Arthritis Foot Disease Activity Index, and health-related quality of life at baseline, 6 and
12 months. Process outcomes will include recruitment/retention rates, data completion rates, intervention adherence
rates, and participant intervention and trial participation satisfaction. Cost-utility and cost-effectiveness analyses will be
undertaken.
Discussion: Outcome measures collected at baseline, 6 and 12 months will be used to evaluate the comparative clinical-
and cost- effectiveness of customised versus prefabricated orthoses for this treatment of early rheumatoid arthritis foot
conditions. This trial will help to guide orthotic prescription recommendations for the management of foot pain for
people with early rheumatoid arthritis in future.
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Background
Rheumatoid arthritis (RA) is the commonest form of in-
flammatory polyarthritis affecting an estimated 645,000
people in the United Kingdom [1–3]. The majority of
people with RA will develop foot and ankle problems
over the course of their disease that will impact upon
their health-related quality of life [1–3]. Large-scale
cross-sectional surveys have demonstrated that foot pain
and walking disability are commonly experienced by
people with RA [4, 5]. In addition, a plethora of mechan-
istic studies employing gait analysis have demonstrated
that people with RA walk slower, with abnormal foot
joint rotations and altered plantar pressure loading char-
acteristics [6–8]. Previous research has demonstrated
that both mechanical and inflammatory factors contrib-
ute to the overall burden of foot disease [8–10]. Accord-
ingly, management strategies for RA-related foot
problems include suppression of disease activity with
disease-modifying anti-rheumatic, biologic drugs, and/or
intra-articular corticosteroids; as well as non-medical
management strategies including, therapeutic footwear
and foot orthoses (FOs) [11].
Relative to studies of those with established disease,
there is a major gap in the current literature concerning
the impact and management of foot impairments in
early RA. Evidence from cohort studies suggest there is
a high prevalence (~ 70%) of foot joint arthritis, pain,
and walking disability in patients with early RA (within
2 years of diagnosis) [4, 5, 12]. Functionally important
kinematic alterations in foot function consistent with
pain avoidance strategies have been detected in partici-
pants with early RA via objective analysis of gait [13].
Moreover, recent qualitative research highlights that
people with early RA can experience a variety of partici-
pation restrictions related to foot impairments [14].
FOs are a recognised non-pharmacological adjunct ther-
apy to standard medical care of people with RA who
present with foot and ankle problems. FOs are designed to
redistribute load from weight bearing sites such as painful
metatarsal phalangeal joints, and to control medial longitu-
dinal arch posture during gait through control of subtalar
and midtarsal joint forces [15–18]. Recent systematic re-
views and meta-analyses indicate that FOs may be benefi-
cial in reducing pain and forefoot pressures in RA [19, 20].
Guidelines for foot care for people with RA typically rec-
ommend the use of FOs in the management of those with
relevant foot problems [11, 21–25]. A recent prospective
cohort study demonstrated that earlier intervention with
FOs for patients with RA predicts favourable foot pain and
disability outcomes [12]. This suggests that prescription of
FOs targeted earlier may provide the best opportunity for
achieving desirable outcomes [12, 26]. However, there have
been no randomised controlled trials to evaluate the effect-
iveness of FOs in early RA.
Prescription practices of FOs for people with RA can
be variable between different clinicians, clinics and ser-
vices, and in the absence of robust evidence these are
largely based upon expert opinion and clinical experi-
ence [27, 28]. To our knowledge there are currently no
treatment guidelines that include specific details regard-
ing the features and types of FOs that provide the great-
est therapeutic benefits for people with RA. In clinical
practice FOs represent a complex intervention that may
or may not include features such as (but not limited to)
arch support, forefoot extension (cushioning), and rear-
foot control (posting) [27, 29]. There are also a wide var-
iety of materials with different properties available ranging
from soft density cushioning devices to rigid supportive
devices [27]. Moreover, FOs are often provided as a pack-
age of care along with footwear advice, FOs wearing ad-
vice, and other foot related co-interventions such as lower
limb muscle stretching/strengthening exercises. Historic-
ally, the reporting of specific details of the intervention in
trials of FOs has generally been poor, however the major-
ity of randomised controlled trials (RCTs) appear to favour
FOs with rearfoot posting, forefoot cushioning and firmer
density orthotic shells [16, 30, 31].
The literature describes two basic approaches to FO
manufacture [32]; i) customised – where FOs are con-
structed from a patient-specific mould or scan, and ii)
prefabricated (also known as ‘off-the-shelf ’) – where
FOs have been mass- produced from a standard last
[33]. In the United Kingdom, standard care tends to in-
volve the use of prefabricated devices unless there is a
specific clinical trigger to warrant escalation to custo-
mised devices such as localised disease activity affecting
the metatarsal heads. In the only direct comparison of
customised versus prefabricated FOs in RA to date;
modest differences in immediate pressure reduction,
pain relief and patient preference for device were re-
ported in favour of customised FOs [19]. Little evidence
exists to support one type of device over the other for
relief of foot pain or disability in the long term in people
with early or established RA. The majority of compara-
tive effectiveness research on customised versus prefab-
ricated FOs has been for relief of pain associated with
plantar fasciitis/plantar heel pain, with most studies
demonstrating similar clinical effectiveness, but a lower
cost with mass-produced prefabricated devices [34–37].
To date, the comparative clinical- and cost- effective-
ness of customised versus prefabricated orthoses in
early RA has not been tested. A recent study investi-
gated clinical- and cost- effectiveness in established RA
[38]. Although this was an exploratory trial with a small
sample size, results indicated a decrease of foot pain
when using customised FOs compared to simple insoles
with no significant cost per quality-adjusted life year
gain [38].
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An element of customisation can now be undertaken
via posting as a form of dose-adjustment and this can be
undertaken on both customised (FO shell manufacture
from a patient-specific mould/scan) and many newer
prefabricated devices. A recent study demonstrated a
dose-response effect using various rearfoot wedging in-
crements to access their effect on plantar pressure vari-
ables, foot segment rotations and foot joint moments in
people who have a pronated foot type [39, 40]. These re-
sults support the concept that foot function can be al-
tered by FOs incrementally according to the desired
degree of correction at the individual level – a key
principle of orthotic dose-adjustment.
Novel orthotic design rules derived from mechanically-based
therapeutic targets [7] have recently been used in a
lab-based mechanistic study to inform the manufacture
of enhanced customised FOs, versus traditionally man-
ufactured customised FOs in people with early RA who
had passively correctable pes planovalgus [41]. While
no long-term outcome data was evaluated, superior im-
mediate mode-of-action determined by gait analysis,
and better patient experience in terms of self-reported
comfort and fit were recorded for highly personalised
devices [41]. Further research is required to determine
whether or not customised FOs result in significant
clinical benefits in order to justify the additional costs
of manufacture.
This study is designed to address an important gap in
the research literature concerning the comparative clin-
ical- and cost-effectiveness of customised versus prefab-
ricated FOs in early RA. Specifically, the primary aim of
this study is to evaluate the comparative clinical- and
cost-effectiveness of prefabricated versus customised
FOs at reducing foot pain over 12 months. The second-
ary aims include the following:-
i) to evaluate the effectiveness, in terms of all
improvements in secondary outcomes including
foot-related disability, Foot Function Index (FFI)
and Foot Impact Scale (FIS) subscales, localised foot
disease activity (RADAI-F5), global disability
(HAQ), and health related quality of life (EQ5D
5 L) achieved at 6 and 12 months following
intervention with either prefabricated or
customised FOs;
ii) to evaluate the effectiveness in terms of overall
patient satisfaction (as measured by a participant
satisfaction questionnaire);
iii) to evaluate the cost-effectiveness of prefabricated in
comparison with customised FOs;
iv) to explore patient opinions, perceptions, and
experiences of benefit following orthotic therapy
(prospective serial interviews and patient
satisfaction questionnaire).
Methods/design
Study design and setting
This trial is designed as a multi-centre two-arm parallel
RCT. A CONSORT flow diagram is presented (Fig. 1),
which outlines the flow of participants through the trial.
Participants will be identified by their Rheumatologist
within the early RA clinics in National Health Services
Grampian, Fife, Lanarkshire, Lothian Health Boards
(Scotland), as well as Dorset Healthcare University
Trust, and Homerton University Hospital (England).
Each site will have an appointed independent outcome
assessor (either a rheumatology nurse specialist or a re-
search nurse) who has received trial protocol training,
and at least one United Kingdom registered Health Care
Professionals Council podiatrist who has either musculo-
skeletal or rheumatology experience working at least at
an National Health Service band 6 level and who has re-
ceived trial specific intervention delivery training. The
intervention will be supplied by the podiatrist and the
outcomes will be collected by the outcome assessor at
each site over three time points: baseline, and 6 and
12 months from baseline. Recruitment commenced May
2016 and the study end (final follow-up, final partici-
pant) is anticipated by 30th April 2019.
Eligibility criteria
Participants will be eligible for inclusion if they are aged
> 18 years and diagnosed with RA < 2 years previously
based on the 2010 ACR/EULAR classification criteria
[42]. Participants will be eligible if they meet the mini-
mum threshold score of ≥20 mm on a visual analogue
scale for foot pain which is localised to any one of the
following: metatarsal phalangeal joints, midfoot, rearfoot,
and/or periarticular tendons surrounding the ankle/sub-
talar joints. If any rearfoot or forefoot bony deformity or
malalignment is present, this must be passively correct-
able as tested through a range of motion assessment.
Participants must not have worn FOs in the previous
6 weeks if provided prior to RA diagnosis.
Participants will be excluded if they had been diag-
nosed with any neurological or endocrine diseases such
as diabetes, which could potentially affect peripheral
nerves, foot structure, function and pain perception.
Additionally, exclusions will occur if they have had any
trauma or injury affecting the musculoskeletal systems
of the lower limb of foot.
Interventions
Both FO interventions (customised versus prefabricated)
represent complex interventions that are comprised of
several components. Given the wide variety of FO pre-
scription practices, the authors have undertaken a partially
pragmatic approach to the FO interventions whereby cus-
tomisation based on participant characteristics and driven
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by clinical design rules will be permitted with certain re-
strictions to avoid prescription variation. Clinical design
rules will guide clinicians on prescriptions based on par-
ticipant’s foot characteristics, for example the presence of
forefoot pain would trigger addition of forefoot cushioning
to the device. Delivery of co-interventions such as foot-
wear advice will also be permitted and will be monitored
for the duration of the study.
Prefabricated foot orthoses
This trial will use an ‘off-the-shelf ’ device (VectOrtho-
tic®, Healthy Step United Kingdom) for the prefabricated
FOs intervention arm. This device is manufactured from
semi-rigid polypropylene and dose (posting) can be ad-
justed according to individual participant characteristics.
The VectOrthotic device is accompanied by “click-in”
rearfoot posts in 2°, 4° and 6° degree doses, as well as ad-
hesive full length top covers. The VectOrthotic has been
used previously as an intervention in an exploratory
study of adults with mechanical foot pain and their use
was associated with a decrease in foot pain relative to
sham orthoses [43]. Extrinsic rearfoot posting will be
provided to correct foot posture according to the static
foot posture measurements using the Foot Posture Index
[44, 45]. Rearfoot posting will be either 0°, 2°, 4° or 6° de-
pending on the degree of supinated to pronated foot
posture. All devices will be ¾ length with a VectOrthotic®
standard top cover (unless additional forefoot protection is
specifically required due to the presence of forefoot pain,
swelling and/or deformity). Should additional forefoot pro-
tection be required, the VectOrthotic® Extra closed-cell
polyethylene top cover (with integrated midfoot support)
extending to the toes will be added to the prescription. The
prescription flow chart is outlined (Fig. 2).
Customised foot orthoses
Participants randomised to this group will receive custo-
mised FOs for both feet. The customised shell will be
obtained from foam box impressions of both feet using
the functional semi-weight-bearing subtalar joint neutral
position method [46]. The participant will be positioned
in a chair with the hip and knee joints at 90° flexion.
The foot will then be placed on the foam box, and the
podiatrist will press the participant’s foot down until the
bottom of the box is reached while maintaining the foot
sole parallel to the floor and the rearfoot aligned in the
subtalar neutral position [47]. Hand pressure will be ap-
plied to the dorsum of the midfoot to prevent supination
Fig. 1 CONSORT flow diagram outlining the flow of participants through the trial
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of the midtarsal joint due to the reactive force of the
foam.
The basic contour of the orthotic shell will be based
on the description of the modified Root style of orthosis,
which is considered to be the most commonly pre-
scribed type of customised orthotic in podiatric practice
[48]. The orthotic will be manufactured from semi-rigid
polypropylene and posted according to information ob-
tained from assessment of foot posture (using the Foot
Posture Index). The shell will be modified to include a
deep heel cup (18 mm) and medial flange [49]. The cus-
tomised FOs will be manufactured by a commercial la-
boratory (Firefly Custom Made Foot Orthoses, Sligo,
Ireland). Extrinsic rearfoot posting will be provided to
correct foot posture according to the static foot posture
measurements using the Foot Posture Index to correct
the rearfoot posture to neutral (calcaneal vertical) using
cast forefoot balancing techniques [50]. This will allow
greater design freedom through rearfoot posture correc-
tion to a precision of the nearest 1°.
The prescription flowchart for this intervention arm is
outlined (Fig. 3). All devices will be ¾ length with a vinyl
top cover (unless forefoot cushioning is specifically re-
quired). Should cushioning be required, 3 mm poron/
vinyl top cover extending to the toes with an integrated
metatarsal raise will be added to the prescription for
manufacture.
Study procedures
An overview of study procedure is outlined in the SPIRIT
table (Table 1). For both intervention arms, each partici-
pant will receive a minimum of 2 one-to-one sessions with
the podiatrist pertaining to the FOs interventions:-.
Session 1
All participants will be assessed in order to inform their
FOs prescription. During this session participants will
receive standard podiatry co-interventions. In the pre-
fabricated FOs arm only, participants will receive their
FOs at this session following the assessment by the po-
diatrist (this is in line with routine clinical practice for
prefabricated FOs – which can be provided ‘off-the--
shelf ’ on the same day). The podiatrist will check
fit-to-feet, and fit-to-shoe or the orthotic, and will seek
subjective information from the participant concerning
initial comfort and fit [41].
Session 2 [custom arm only]
Participants in the customised FOs arm a will return for
the fitting of either their customised FOs within 2–
3 weeks of their session 1 appointment (this is in line
with routine clinical practice where there is a gap be-
tween initial assessment and fitting to allow for manu-
facture of the customised device). At fitting stage, the
podiatrist will check fit-to-feet, and fit-to-shoe or the
orthotic, and will seek subjective information from the
participant concerning initial comfort and fit [41].
Session 3
All participants will return for a review of their orthotic
device 6–8 weeks after initial fitting of the respective FO
device at either session 1 (prefabricated) or session 2
(customised). At this appointment the podiatrist will re-
peat the initial assessments that led to the prescription
to ensure the orthotic device is still appropriate for each
participant. The podiatrist will review subjective infor-
mation from the participant concerning comfort, fit, and
self-reported efficacy, including whether or not there has
Fig. 2 Summary of prefabricated foot orthoses prescription protocol
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Table 1 SPIRIT table for study procedure
Pre-study screening/
consent
Baseline Randomisation
/Clinical visit 1
Clinical
visit 2
Clinical
visit 3
6 months
follow up
12 months
follow up
−1 0 T1a T2b T3 F1 F2
Enrolment
Eligibility screen X
Informed consent X
Allocation X
Measurements
FFI pain X X X
FFI disability X X X
FFI functional limitation X X X
FIS-RA X X X
EQ-5D-5 L X X X
HAQ X X X
DAS-28 X X X
CSRI X X
Interventions
Customised foot orthoses X X X
Prefabricated foot orthoses X X
FFI Foot function index, FIS-RA Foot impact scale for rheumatoid arthritis, HAQ Health assessment questionnaire, DAS-28 disease activity score 28 joints, CSRI Client
service receipt inventory
T1a randomisation was triggered by the intervention clinician at the first clinical visit using the online system
T2bfor customised FO group, manufacture required an additional fitting appointment approximately 2 weeks following clinical visit 1
Fig. 3 Summary of customised foot orthoses prescription protocol
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been any change in symptoms and/or short-term benefit
over the previous 6–8 weeks using Visual Analogue and
Likert Scales.
Unscheduled foot orthoses review sessions
From initial fitting of FOs to the end of the trial period
at 12 months from baseline, self-referral for review of
FOs will be permitted for participants in either treat-
ment arm where there are adverse reactions, and/or loss
of or damage to foot orthoses. To facilitate this, partici-
pants will be provided with the contact details for their
podiatrist in order to book unscheduled FOs review
sessions.
Study outcome measures
The primary outcome measure will be foot pain, which
will be measured at 12 months using the Foot Function
Index pain subscale (FFIpain), which is a composite score
for foot pain [51]. The FFI is a widely used, valid and re-
liable self-administered questionnaire consisting of 23
items grouped into 3 domains: foot pain (9 items), dis-
ability (9 items), and activity limitation (5 items) [51]. At
present, the FFI is one of the few instruments for scoring
foot-related disability that has been rated positively for
responsiveness-to-change [6] and has been employed fre-
quently as a primary outcome measure in several previous
RCTs of FOs for people with RA [16, 52, 53]. For each
subscale, items are rated using a 100 mm Visual Analogue
Scale, and a composite score is calculated by summing
items and dividing by the total number of items in that
subscale. As outlined in the original scoring system [51]
any item marked as not applicable will be excluded from
the calculation of the total possible score. A higher score
is indicative of more severe foot pain and disability.
Secondary outcome measures
The remaining FFI subscales for disability (FFIdis) and
functional limitation (FFIfl) will be measured as second-
ary outcomes. In addition, the Foot Impact Scale for RA
(FISRA) will be adopted as a secondary outcome measure
to provide a disease-specific measurement of localised
disease impact [54]. This is a 51-item questionnaire with
dichotomous scoring system (true/not true responses)
and two subscales for impairment/footwear and activity
limitation/participation restriction. Responses in the true
column are summated to give a total score for each
subscale.
The EQ-5D-5 L [55] is a valid and reliable measure of
health-related quality of life in adults and will be used
primarily for the purposes of the cost-utility analysis as-
pect of the embedded health economic evaluation of the
intervention. The EQ-5D-5 L is a 5-item questionnaire
that requires a response on a 5-point Likert scale, and
responses will be used to calculate quality-adjusted life
years gained.
A satisfaction questionnaire consisting of numerical
rating and Likert scales will be used to measure orthotic
device comfort, fit, and self-reported efficacy symptoms
and activity levels. Participant reporting of adverse
events will also be permitted to provide further com-
ments using open-ended responses within this question-
naire. In addition, a small random sample of participants
will be invited to take part in an interview to explore ex-
periences of the interventions and perceptions of im-
proved/deteriorated outcomes.
Global disability will be measured using the Health
Assessment Questionnaire [56]. Global disease activity
will be measured using the Disease Activity Score using
28 joints [57]. Disease duration will be recorded as the
time in months from onset of symptoms and time in
months from disease diagnosis as self-reported by the
participant.
Health economic evaluation
The health economic analysis will conform to a superior-
ity trial analysis and will address both cost-effectiveness
(cost per unit of improvement of the primary outcome –
the FFIpain) and cost utility using quality-adjusted life
years measured using the EQ-5D-5 L.
Costs of treatment in either arm will be considered from
a societal perspective. For prefabricated FOs, the costs col-
lected will include the unit cost of each prefabricated de-
vice prescribed, and staff time for assessments and review
appointments. Similarly for customised FOs, the costs col-
lected will include costs associated with manufacture of
FOs including materials and staff time, as well as staff time
for assessments and review appointments. In addition, the
costs of systemic therapies in terms of biological agents,
disease-modifying anti-rheumatic drugs and non-steroidal
anti-inflammatories will be recorded for both trial arms.
For both trial arms and in addition to FOs related
costs, we will record the use of foot care services
throughout the trial. These will be costed using National
Health Service pay and prices or, where appropriate,
using other (e.g. shop or internet bought) sources. Out
of pocket expenses for over the counter products, and
complementary and alternative therapies, as well as
travel to/from health appointments and time off work
will also be included. All cost data will be collected using
a combination of participant medical records, and an
adapted version of the Client Service Receipt Inventory
[58] resource use checklist. Data on programme costs
and those on further impacts will be aggregated and the
statistical significance of differences in cost per patient
between trial arms assessed by appropriate methods de-
pending on the distributional characteristics of the data.
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Sample size
In the absence of availability of detailed information on
the clinical meaningful difference in outcome measured
using the FFI pain subscale, the calculation of our de-
sired effect size was based upon previous findings from
an FOs trial for people with RA [52]. This trial evaluated
6 month FFI pain subscale scores at 6 months following
intervention with either a functional FO versus a
non-functional placebo-type flat FO. Mean difference at
6-month outcome (9.93) and pooled standard deviation
(19.77) values were obtained from this study to calculate
a standardised mean difference. For a two-tailed hypoth-
esis, to detect a standardised mean difference of 0.5
(9.93/19.77) (a medium to large effect size) at 0.05 sig-
nificance, 0.8 power and 20% attrition (based on the ran-
domised controlled trials by Woodburn et al. [30]), we
require 160 participants (80 per arm) [Statistics Calcula-
tors, 2015].
Recruitment
Participants meeting the selection criteria will be re-
cruited from ‘early arthritis’ rheumatology outpatients’
clinics within the National Health Service Health
Boards/Trusts of the participating centres.
Randomisation
Randomisation will be conducted via permuted block.
This means there will be variable size blocks with alloca-
tion to customised (a) or prefabricated (b) for 160 partici-
pants. In order to conceal the process from local trial site
personnel, this will be administered via web randomisa-
tion. Permuted block randomisation will be performed
using a bespoke Fortran program with an intrinsic
pseudo-random number generator and the resulting table
will be accessed by a bespoke Fortran web application on
a secure server, to provide and log allocations sequentially
on-line as required. Each intervention podiatrist will have
access to a web ‘link’ which will randomly allocate the par-
ticipants into each arm. This will be undertaken by the
intervention podiatrists once they have concluded their
respective foot assessments.
Allocation concealment
Allocation will be conducted once eligibility checks have
been performed and only once the participant has been
registered in the trial. The central randomisation admin-
istrator who will follow the web based allocation will be
masked to the identity of participants and all primary
and secondary outcomes.
Blinding/masking
The nature of this trial dictates that blinding of the clini-
cians delivering interventions and the participants is not
possible. However the outcome assessor will be blind to
group allocation, and will not be involved in any delivery
of therapeutic interventions. Participants will be
instructed not to disclose their group allocation to the
outcome assessor. Any breaches in blinding protocol will
be recorded.
Analysis
Data will be analysed according to the intention-to-treat
principle. Data will be explored to determine whether or
not potential confounders need to be accounted for in
the final analysis. Should we detect any imbalances be-
tween intervention groups, we expect that the analysis
of the primary outcome (FFI pain subscale) will be con-
ducted using an analysis of covariance (ANCOVA) with
adjustment for relevant baseline values and potential
confounders. For example, to account for systemic dis-
ease activity as a covariate, the FFI pain subscale change
scores will be adjusted according to both FFI pain sub-
scale baseline scores and the change scores of the Dis-
ease Activity Scale for 28 joints between baseline and
follow up. Statistical methods for secondary/additional
analyses: Similarly, for comparison of all other secondary
outcomes, between group scores from baseline to
12 months will be compared using ANCOVA with ad-
justment for baseline values and potential confounders.
All estimates for primary and secondary outcomes will
be reported with estimated effect sizes alongside 95%
confidence intervals.
Health economics analyses
Outcomes will be assessed using the primary trial out-
come and the EQ-5D-5 L. The primary analysis will be
undertaken at 12 months from an National Health Ser-
vice and Personal Social Services perspective. A broader
perspective including patient’s personal expenditures will
be included in a sensitivity analysis. Incremental cost ef-
fectiveness ratios will be computed by comparing the
costs and outcomes of both arms of the trial. The differ-
ence in effectiveness will be expressed in terms of the
change in score on the primary outcome measure (cost--
effectiveness analysis). The difference in utility will be
expressed in terms of quality adjusted life years calcu-
lated using patient reported EQ-5D 5 L data. This will
be used in a cost utility analysis to calculate the incre-
mental cost per quality adjusted life years gained.
Missing data
For missing data (participant withdrawal or interim
missing data), the plausibility of missing data models
‘missing at random’, ‘missing completely at random’,
‘missing not at random’ will be ranked by the trial
personnel (informed by the available trial data). The
most plausible missing data model will be selected and a
sensitivity analysis will be conducted accordingly to
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explore the effect of departures from assumptions made
in the primary analysis. Upon completion of sensitivity
analyses, an appropriate method of missing data imput-
ation will be selected.
Ethical consideration
Ethical approval for this study has been obtained by the
East of England – Essex Research Ethics Committee Ref:
15/EE/0410. Registration of this RCT has been com-
pleted with the ISRCTN registry: ISRCTN31652.
Discussion
FOs have been used clinically for many decades for the
treatment of foot pain in patients with RA, although
their effectiveness has not been rigorously evaluated as a
management method. Despite this, foot care recommen-
dations feature in many United Kingdom and European
clinical guidelines. However, the level of supporting evi-
dence is low, mainly at ‘good clinical practice’ and ‘ex-
pert opinion’ agreement level [26]. This could be due to
various reasons: the numerous types of FOs available in
the market place; the variation of prescription habits be-
tween clinicians; and the biomechanical effects of the
FOs on the lower limb, which we believe to be clinically
beneficial are limited throughout the literature [59]. Fur-
ther, customised orthoses commonly follow the ‘subtalar
joint neutral theory’ for foot morphology even when cri-
ticised for its reliability and validity [60]. Three reviews
investigating the effect of FOs in RA patients report a
general consensus that FOs are beneficial [61–63], yet
no insight is given into prescription guidelines or treat-
ment recommendations.
This trial protocol has been designed to provide robust
results on orthotic treatment and guidelines in an RA
cohort. This is a randomised trial which includes con-
cealed allocation using a web based system, blinding of
outcome assessors, blinded data analysis and the use of
outcome measures with proven reliability and validity in
pain, satisfaction, disease activity and functional limita-
tion. Further, all podiatrists will be trained and provided
with prescription protocols (Figs. 2 and 3) to follow en-
suring similar prescriptions between the 6 recruitment
sites.
This trial aims to provide clinically relevant and robust
evidence in regards to clinical outcomes, patient satisfac-
tion and cost-effectiveness. Each of the research questions
that will be investigated in this study will provide National
Health Services with further knowledge about the use of
FOs in this selected patient cohort. Clinical effectiveness
evaluation will provide evidence for the National Health
Service to practice around the highest standards as well as
being aware of patient satisfaction. We anticipate that this
project will provide vital evidence and thus guidance to in-
form clinical decision making in future.
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